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Background: Cardiovascular disease in Asia has reached epidemic proportions in recent
years. Use of drug eluting stents in Asians has rapidly expanded with varying penetration
rates across different countries. The XIENCE V INDIA Study included ‘real world’ patients
who underwent XIENCE V stent implantation to assess short and intermediate term
outcomes in Indian patients with diverse risk factors.
Objective: To evaluate 3-year clinical outcomes in a cohort of ‘real world’ Indian patients
with CAD being treated with XIENCE V Everolimus Eluting Coronary Stent System.
Methods: 1000 patients were enrolled from 18 sites in India between June 2008 and March
2009. Patients were included if their index procedures were completed using only XIENCE
V. There were no clinical or angiographic exclusions. An independent Clinical Events
Committee adjudicated all endpoint-related events. The primary endpoint was stent
thrombosis rate annually through to 3 years as defined by the Academic Research Con-
sortium criteria. The co-primary endpoint was the composite rate of cardiac death and
myocardial infarction at 1 year.
Results: At 1-year the primary endpoint of definite/probable stent thrombosis rate was
0.51%. No additional very late stent thrombosis was reported through a 3-year follow up.
The composite endpoint of cardiac death and any myocardial infarction was 1.9%, 2.7%
and 3.1% at 1, 2 and 3 years respectively.hcare.com, meenakshi.kar@fortishealthcare.com (A. Seth).
ciety of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 0 2e3 0 8 303Conclusion: Despite the high risk population of coronary artery disease, the use of XIENCE
V in ’real world’ Indian patients was associated with very low clinical event rates upto
three years of follow up.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
India is currently experiencing a rapid economic, demographic,
lifestyle transition and non-communicable diseases such as
coronary artery disease (CAD) and diabetes mellitus have
overtaken infectious diseases as the most important cause
of death.1,2 Due to its large population, India currently repre-
sents a quarter of the world’s chronic heart disease burden.3,4
Cross-sectional studies estimate the prevalence of coronary
heart disease in India to be 34% in rural and 810% in
urban areas, representing a two-fold rise in rural areas and
a six-fold rise in urban areas, between the years 1960 and
2000.5e8
Traditionally coronary heart disease manifests almost 10
years earlier in the Indian population when compared to the
rest of the world suggesting that unique environmental and/
or genetic risk factors exist for this population.8,9 There is also
a high prevalence of diabetes, hyperlipidemia and glucose
intolerance in the CREATE registry of treatment of acute cor-
onary syndrome in India.10 However, there is no data on long
term outcome of Indian patient treated by DES, keeping in
mind that this population has a unique spectrum of high risk
factors for restenosis.
Long term surveillance studies using DES may help eluci-
date mechanisms correlated to death, myocardial infarction,
and late stent thrombosis risks not observed during controlled
pre-market trials.11 Finally, adjunctive anti-platelet therapy
may be a critical factor in optimizing long termDES safety.12,13
Despite established guidelines that recommend 6e12 months
of dual anti-platelet therapy, patients with DES implants oc-
casionally stop taking their medication early.
We report the 3-year clinical follow up of the XIENCE V
INDIA single arm prospective study which evaluated the
outcomes following implantation of the XIENCE V stent in
complex lesions in a ‘real world’ 1000 Indian patients when
used by a broad group of physicians at 18 centers across the
country. Compliance to anti-platelet therapy in an Indian
population undergoing PCI treatment has also been docu-
mented in this XIENCE V INDIA single arm study.
This study represents the only large and long term study of
its kind, evaluating a second generation DES among high risk
Indian population.2. Methods
2.1. Study design and patients
XIENCE V INDIA is a prospective, open-label, multi-center,
observational, single arm study designed to evaluate the
safety of the XIENCE V everolimus eluting stent duringcommercial use in real-world settings. Protocol approval was
obtained by the medical ethics committee of each partici-
pating institution and all patients gave written informed
consent. All patients who could provide informed consent and
whose procedures were completed with only XIENCE V
during the index procedure were considered enrolled in this
study. There were no additional clinical or angiographic
exclusion criteria. Enrollment of patients was done via the
interactive voice or web response enrollment service (Cova-
nce, New Jersey). The study was conducted in compliance
with the Central Drugs Standard Control Organization
(CDSCO) approved protocol and the Declaration of Helsinki,
International Organization for Standardization (ISO) 14155,
Guidelines for Clinical Trials on Pharmaceutical Products in
India e Good Clinical Practice (GCP), International Conference
on Harmonization (ICH) of Technical Requirements for
Registration of Pharmaceuticals for Human Use, and GCP
Guidelines. Between 03 June 2008 and 13 March 2009, 1000
patients were consecutively enrolled at 18 sites in India. Ten
patient records were excluded from the analysis population
due to enrollment errors, leaving an analysis population of
990.
2.2. The XIENCE V everolimus eluting stent
A detailed description of the device has been published pre-
viously.14 XIENCE V received CEmark approval on 30 January
2006, DCGI marketing approval on 05 July 2006 and US FDA
approval on 02 July 2008. Stents were available in diameter
sizes of 2.25e4.0 mm and lengths of 8e28 mm.
2.3. Study procedure
The treatment strategy and post procedural medication
regimen was determined by the investigator. It was recom-
mended that each enrolling investigator review the In-
structions for use and assess the indications,
contraindications, warnings and precaution sections with
respect to risks and benefits for treating potential patients.
Protocol recommendations for anti-platelet therapy suggested
indefinite duration of aspirin, alongwith at least sixmonths of
clopidogrel extended to at least 12 months as recommended
by ACC/AHA/SCAI guidelines in patients presenting with
acute coronary syndromes.15e17
2.4. Follow up
Clinical follow up was scheduled at 14, 30 and 180 days, and
annually through 3 years, either by telephone contact or office
visit. Each time point included collection of data regarding
adverse events and use and changes in concomitant
medications.
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All clinical endpoint events, including stent thrombosis (ST),
death, myocardial infarction (MI), coronary revascularization
and major bleeding, were adjudicated by an independent
Clinical Events Committee (CEC), Cardiovascular Research
Foundation, New York, New York. The Data Safety Monitoring
Board (DSMB) (Axio, Seattle, Washington) reviewed the cu-
mulative safety data on a regular basis.
The primary endpoint was the incidence of ST rates
annually through to 3 years as defined by the Academic
Research Consortium (ARC) definition.18 The co-primary
endpoint was the composite rate of cardiac death and any
ARC definedMI at one year. Secondary endpoints included the
composite rate of all deaths, any MI and any repeat revascu-
larization; the composite of cardiac death and any MI; com-
posite rate of all death and any MI; target lesion failure (TLF),
defined as the composite rate of cardiac death, any MI
attributed to the target vessel, and clinically indicated target
lesion revascularization (CI-TLR); all death; any MI; revascu-
larization (target lesion, target vessel [TVR], and non-target
vessel) (PCI and coronary artery bypass graft surgery
[CABG]); major bleeding complications (by TIMI definition);
and clinical device and procedural success.
2.6. Source document verification
Source document verification was routinely performed in 30%
of randomcases and 100% of all reported adverse events at the
time of the study conduct. For sites with low rates of adverse
event reporting, additional monitoring visits and source
document verification checks were performed.
2.7. Definitions
2.7.1. Death
All deaths were considered cardiac unless an unequivocal
non-cardiac cause could be established. Specifically, any un-
expected death, even in patients with coexisting potentially
fatal non-cardiac disease (e.g. cancer, infection), were classi-
fied as cardiac.
2.7.2. Cardiac death
Any death due to immediate cardiac cause (e.g. MI, low-output
failure, fatal arrhythmia). Unwitnessed death and death of
unknown cause were classified as cardiac death. This
included all procedure-related deaths including those related
to concomitant treatment.
2.7.3. Myocardial infarction
MI classification and criteria for diagnosis were defined ac-
cording to the ARC18 All late events that were not associated
with a revascularization procedure were considered sponta-
neous. One blood sample was taken from each patient within
the post-procedure hospitalization period for the analysis of
CK-MB or troponin levels.
2.7.4. Target lesion revascularization
TLR was defined as any repeat percutaneous intervention of
the target lesion or bypass surgery of the target vesselperformed for restenosis or other complication of the target
lesion. The target lesion is defined as the treated segment
from 5 mm proximal and 5 mm distal to the stent.
2.7.5. Target vessel revascularization (TVR)
TVR is defined as any repeat percutaneous intervention or
surgical bypass of any segment of the target vessel. The latter
is defined as the entire major coronary vessel proximal and
distal to the target lesion including upstream and down-
stream branches and the target lesion itself.
2.7.6. Stent thrombosis
Was categorized as acute (<1 day), subacute (1e30 days), late
(>30 days) and very late (>1 year) and was defined according
to the ARC guidelines as follows: definite: acute coronary
syndrome and angiographic or pathologic confirmation of
stent thrombosis; probable: unexplained death  30 days or
TV-MI without angiographic information; and possible: un-
explained death > 30 days after stent placement.
2.7.7. Clinical device success
Successful delivery and deployment of the study stent (in an
overlapping stent setting a successful delivery and deploy-
ment of the first and following study stent) at the intended
target lesion and successful withdrawal of the stent delivery
system with attainment of final residual stenosis of less than
50% of the target lesion by QCA (by visual estimation if QCA
unavailable), without use of a device outside the assigned
treatment strategy. Bailout patients were included as clinical
device success only if the above criteria were met.
2.7.8. Clinical procedure success
Clinical device success without the occurrence of cardiac
death, MI not clearly attributed to a non-target vessel and/or
CI-TLR during the hospital stay with amaximumof first seven
days post index procedure. In multiple lesions setting each
lesion must have met clinical procedure success criteria.
2.7.9. Thrombosis in myocardial infarction (TIMI) bleeding
classification
Major bleeding per TIMI classification included intracranial
hemorrhage, or a 5 g/dL decrease in the hemoglobin con-
centration, or a 15% absolute decrease in the hematocrit.
2.8. Statistical analysis
The sample size for the study was determined for descriptive
purposes only. Descriptive analyses were performed on the
intent-to-treat population.3. Results
A total of 1000 patients were enrolled in the study. As defined
by the protocol, all results are presented for the intent-to-treat
population. Ten patient records were excluded from the
intent-to-treat (ITT) population (analytical population) due to
enrollment errors, leaving an ITT population of 990. Patient
follow up is presented in Fig. 1. 938 of 990 patients (94.7%)
continued in the study at 3 years.
Fig. 1 e Patient flow and follow up in XIENCE V INDIA
study through 3 years.
Table 2 e Baseline coronary lesion characteristics of
subjects enrolled in XIENCE V INDIA study.
Baseline lesion characteristicsa ITT
population
(nL ¼ 1324b)
Lesion length (mean  SD, mm) 16.9  6.4
Longer lesions 20 mm (%) 39.6
Pre-procedure RVD (mean  SD, mm) 2.89  0.4
AHA/ACC lesion type B2 or C (%) 46.8
Bifurcation lesion (%) 4.4
Left main (%) 0.7
LAD (%) 52.3
Ostial location (%) 6.4
Pre-procedure % diameter stenosis
(mean  SD)
87.7  9.7
TIMI flow of 0 (%) 10.4
Chronic total occlusion (TIMI 0 for 3 months)
(%)
2.4
a Visual assessment by the investigator.
b nL ¼ number of lesions.
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Table 1. Male patients accounted for 84% of the study popu-
lation and the mean age was 58  10 years. 44% of patients
were diabetic, with 9% requiring insulin. The percentage of
patients presented with hypertension was 62% and withTable 1 e Baseline patient characteristics and risk factors
of subject enrolled in XIENCE V INDIA study.
Baseline characteristics and risk factors ITT
population
(n ¼ 990)
Age (mean  SD, years) 58.23  10.16
Male (%) 84
Body mass index 30 kg/m2 (%) 14.4
Current smoker (%) 10
Family history of premature CAD (%) 24
Hypertensiona (%) 62
Dyslipidemiaa (%) 33
Diabetes (%) 44
Treated with Insulin (%) 9
Prior cardiac intervention (%) 13
Prior myocardial infarction (%) 21
Within 2 months prior to index procedure 9
Acute coronary syndrome (%) 19
Current angina status: unstable angina (%) 57
Braunwald class III (%) 19
a Treated with medication.dyslipidemia requiring medication was 33%. In addition, 21%
of patients had experienced a prior myocardial infarction,
with 9% of those within the 2 months prior to the index pro-
cedure. The percentage of patients presented with an acute
coronary syndrome (ACS) was 19%. In the ITT population 57%
of patients presented with Unstable Angina of which 19%
were Braunwald Class III. There were 14.4% of patients with
BMI 30 kg/m2.
Lesion and procedural characteristics are summarized in
Table 2. As assessed by the treating physician, themean lesion
length was 16.9 mm (40% of lesions were 20 mm in length)
and the mean reference vessel diameter (RVD) was 2.9 mm. In
the ITT population, 47% of the lesions were of either AHA/ACC
lesion Type B2 or C. Themajority of treated lesionswere in the
left anterior descending artery (52%) and LMCA constituted
0.7%. The percentage of bifurcated lesions were 4% and 6.4%
were ostial lesions. The percentage of lesions that had a TIMI
flow of 0 was 10.4% with 2.4% of these being present for 3
months. Patients were treated according to standard inter-
ventional techniques with high acute device and procedure
success rates of 100% and 99.6% respectively.Early: 0 to 30 days, Late: 30 days to 1 year and Very Late: > 1 year. 
Fig. 2 e Definite/probable stent thrombosis rates in XIENCE
V INDIA study through 3-year follow up.
Table 3 e Adjudicated hierarchical major adverse cardiac
events at 1, 2 and 3 years in XIENCE V INDIA study.
1-year ITT
population
(n ¼ 986)
2-year ITT
population
(n ¼ 970)
3-year ITT
population
(n ¼ 957)
Cardiac death and MI (%) 1.9 2.7 3.1
All death and MI (%) 1.9 2.7 3.1
All death, all MI and all
revascularization (%)
2.9 4.3 5.1
Target lesion failurea (%) 2.4 3.3 3.9
a Cardiac death, MI attributed to target vessel and clinically indi-
cated target lesion revascularization.
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rate through 3 years, was 0.52%. At one year the ST rate was
0.51%, with no further events up to completion of 3-year
follow up. The definite/probable early (30 days) and late (one
year) ST rates were 0.3% and 0.2%, respectively (Fig. 2).
The percentage of patients who remained on dual anti-
platelet therapy at 1 2, and 3 years were 96.9%, 93.1% and
91.5% respectively. Major bleeding by TIMI classification was
noted in 0.1% of patients through to 3 years.
The co-primary endpoint rate of the composite of cardiac
death and any myocardial infarction (MI) at 1 year was low at
1.9% (see Table 3). The rate of ARC defined patient-oriented
(hierarchical) composite endpoint (all death, all MI and all
revascularization) was 2.9%, 4.3% and 5.1% at 1, 2 and 3 years
respectively (see Table 3). The overall death rate was 0.9%,
1.6% and 2% at 1, 2 and 3 years respectively. The MI rate was
1.3%, 1.5% and 1.7% at 1, 2 and 3 years respectively. The Q-
waveMI contributed to only 0.5% of the total MI rate of 1.7% at
3 years (see Table 4).
At 1, 2 and 3 years, the composite rate of target lesion
failure (TLF; defined as composite of cardiac death, MI related
to the target vessel and TLR) was 2.4%, 3.3% and 3.9%
respectively (see Table 3). All revascularizations were
considered clinically indicated and the TLR rate was 1.2%,
1.4% and 1.6% at 1, 2 and 3 years respectively (see Table 4).4. Discussion
The data presented shows that the XIENCE V everolimus
eluting coronary stent is safe and efficacious when used in a
real world patient population in India. The compositeTable 4 e Non-hierarchical major adverse cardiac events at 1,
1 year ITT
population (n ¼ 986)
All death (%) 0.9
Cardiac death (%) 0.9
All MI 1.3
Q-wave MI (%) 0.4
Non Q-wave MI (%) 0.9
All Revascularization (%) 1.6
TLR (%) 1.2a
a Not clearly attributed to a non-target vessel.endpoint of cardiac death and any myocardial infarction (MI)
was low at 3.1% in this ‘real world’ Indian population with
CAD. The primary endpoint of stent thrombosis was low at
0.51% at one year which did not increase beyond this upto 3
years (0.52%). The prevalence of diabetes, a known CAD risk
factor in the Asian population,19 is higher in this study when
compared to other published studies.20e22 Forty four percent
of patients in XIENCE V INDIA had diabetes mellitus
compared to 26% of patients in the SPIRIT V study. Despite
this, the clinical outcomes in this study were comparable to
those of other studies with lower risk populations. When
compared to patients from SPIRIT V, XIENCE V INDIA pa-
tients respectively were younger (mean age of 63 years vs. 58
years), presentedwith less incidence of smoking (24% vs. 10%),
and less family history of premature coronary artery disease
(34% vs. 24%). They also presentedwith less dyslipidemia (33%
vs. 59%). Of note, the diagnosis of dyslipidemia was made by
the investigator and was based on whether or not the patient
was treated with lipid-lowering medication. It has previously
been shown in India that patients from lower socio-economic
backgrounds were less likely to receive lipid-lowering drugs
and coronary revascularization than their wealthier counter-
parts.10 In these cases, lifestyle changes might be the
preferred treatment for dyslipidemia. However, as this study
did not collect patient socio-economic data, this hypothesis
remains unconfirmed.
Despite the fact that, in general, the Indian population is
considered more likely to present with known predictors of
restenosis and TLR, the 2-year and 3-year non-hierarchical
TLR rate was appreciably lower at 1.4% and 1.6% respectively
in this study than the TLR rates in other reports with similar
patient populations.23 This findingmay be in part attributed to
the higher threshold for repeat revascularization (TLR/TVR)
for minimally symptomatic patients in the Indian cardiology
practice. This may be attributed to both socio-economic and
cultural issues. Barely 10% of Indian households (with at least
one member of the family covered) are covered by medical
insurance24 thus leading to possible caution for subjecting to
repeat revascularization at low symptom level. As shown in
the CREATE registry, approximately 75% of patients in India
pay directly for their own treatment.10 In addition, diagnostic
tests such as EKG, CK-MB and troponin measurements may
not have been routinely performed in patients seeking care
during follow up.
Late stent thrombosis is a major concern following drug-
eluting stent implantation in interventional cardiology and2 and 3 years in XIENCE V INDIA study.
2 year ITT
population (n ¼ 970)
3 year ITT
population (n ¼ 957)
1.6 2.0
1.6 2.0
1.5 1.7
0.5 0.5
1.0 1.1
2.4 2.7
1.4 1.6
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dictor of stent thrombosis.25 At 3 years, the overall rate of ARC
defined definite and probable stent thrombosis in this study
was 0.52%. It is possible that there might have been some
under-reporting of adverse events in this study; every effort
was made to obtain all adverse events through diligent
monitoring. The low rates of stent thrombosis in XIENCE V
INDIA are consistent with numerous other trials, and are
likely to be due to an optimal combination of thin fracture-
resistant cobalt-chromium struts, low dose of everolimus
elution, and well-known thromboresistant non-inflammatory
proprieties of the fluorinated polymer.26 In addition, therewas
a high rate of compliance to aspirin and clopidogrel dual anti-
platelet therapy. At 3 years 93.3% of patients were still taking
aspirin, 92.8% clopidogrel and 91.5% remained on dual anti-
platelet therapy. Low event rates seen at one year from the
XIENCE V INDIA study were maintained through 3 years
which further demonstrate the long term safety and efficacy
of XIENCE V in this real-world population.
4.1. Limitations of the study
This study was limited by the single arm nature of the design
and thus the inherent lack of a control arm for direct com-
parison. Lesion characteristics were assessed and reported by
the investigator at the time of the procedure. No conclusion
can be drawn from this study regarding outcomes in specific
patient subsets. For example, 2.4% (24 of the 990) patients had
a diagnosis of chronic total occlusion (CTO). Thus despite the
high procedural success in this study in general, procedural
outcomes in subgroups need to be examined in larger
numbers of patients.5. Conclusion
In conclusion, in these real world Indian patients undergoing
PCI, despite a high prevalence of cardiac risk factors, low 3-
year rates of stent thrombosis, cardiac death and myocardial
infarction demonstrate long term safety and efficacy of
XIENCE V stent.Funding
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